A new study released today by the Pacific Research Institute finds that a program to give discounted prescription drugs to poor Americans is riddled with abuse, has created a perverse incentive for providers to profit instead of effectively serve the [...]
New research from Avalere finds that hospitals in California, North Carolina, and New York will experience the greatest drug payment cuts nationally, ranging from $126M to $62M, as a result of recent changes to the way Medicare pays for 340B [...]
The 340B Drug Pricing Program has driven hospitals to play a greater role in oncology care due to more favorable reimbursement, as evidenced by the fact hospital outpatient facilities saw their average profit margins on Medicare Part B hospital cancer [...]
The Trump administration recently announced a $1.6 billion cut to the badly abused “340B” program, which forces pharmaceutical companies to sell medicines to hospitals that treat significant numbers of poor patients at steep discounts. Read the full article on Pacific [...]
The nation’s most influential science advisory group was set to tell Congress on Tuesday that the U.S. pharmaceutical market is not sustainable and needs to change. Read the full article on California Healthline here.
Experts shared their sometimes conflicting ideas for making prescription drugs more affordable during a hearing of the Senate Health, Education, Labor and Pensions (HELP) Committee Tuesday. Read the full article on MedPage Today here.
The U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP), led by Chairman Lamar Alexander (R-Tenn.) and Ranking Democrat Patty Murray (D-Wash.) recently held a hearing on Capitol Hill on the enormously important issue of drug pricing. Read the [...]
CAR T-cells first hit the headlines in 2012 after saving the life of a young girl in Philadelphia, Emily Whitehead, who was running out of options to treat her aggressive, relapsed leukemia. Doctors removed some of her T-cells, genetically modified them [...]
BRG Analysis Documents Hospitals’ 340B Profit Margins of Almost 50 Percent and 340B Discounts Exploding by Over 300 Percent from 2010 to 2015 340B Program is Driving Cancer Care to More Expensive Hospital Setting, Increasing Costs to Patients, Medicare, and [...]